Reading MODD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MODD free→Reading MODD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MODD free→QuarterlyIQ Insights · MODD
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Stock Option Awards to Named Executive Officers On May 14, 2026, the board of directors of Modular Medical, Inc. (the “Company”) awarded 11,218 stock options to Paul DiPerna, the Company’s Chairman, President, Chief Financial Officer and Treasurer, and 4,674 stock options to Kevin Schmid, the Company’s Chief Operating Officer. The stock options hav…
Entry into a Material Definitive Agreement. On April 19, 2026, Modular Medical, Inc. (the “Company”) entered into a Placement Agency Agreement (the “Agreement”) with Maxim Group LLC (the “Placement Agent”), relating to a registered direct offering (the “Offering”) of 750,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), referred to as the “Shares.” The gross proceeds to the Company from the Offering will be approximately $3.375 million, before deductin…
of Form 8-K, the information regarding the Reverse Split (as defined below) contained in
Entry into a Material Definitive Agreement. On March 3, 2026, Modular Medical, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (the “Placement Agent”) and securities purchase agreements (the “Securities Purchase Agreements”) with multiple investors, relating to a best-efforts offering (the “Offering”) of (i) 62,098,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) pre-funded wa…
Creation of a Direct Financial Obligation or an Obligation under an Off Balance Sheet Arrangement of the Registrant. The disclosures in
Entry into a Material Definitive Agreement Credit Facility On February 23, 2026, Modular Medical, Inc. (the “Company”) issued a secured promissory note (the “Note”) to James E. Besser (“the Lender”), the Company’s chief executive officer, that provides the Company with a $350,000 revolving credit facility with all amounts being drawn down by the Company thereunder being due and payable, subject to acceleration in the event of a default, on March 25, 2026 (the “Maturity Date”). Interest at the…
of Form 8-K, the information regarding the increase in authorized shares contained in
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on June 30, 2025, Modular Medical, Inc. (the “Company”) received written notice (the “Notice”) from the Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), for the last 30 consecutive business days, had closed below the minimum $1 per share and, as a result, the Company is not…
Entry into a Material Definitive Agreement. On December 10, 2025, Modular Medical, Inc. (the “Company”) entered into an Underwriting Agreement (the “Agreement”) with Newbridge Securities Corporation (the “Underwriter”), relating to a firm commitment underwritten offering (the “Offering”) of (i) 12,173,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), referred to as the “Firm Shares,” and (ii) accompanying warrants exercisable to purchase up to 6,086,50…
Entry into a Material Definitive Agreement. As previously disclosed, in May 2023, Modular Medical, Inc. (the “Company”) entered into an underwriting agreement with Newbridge Securities Corporation (“Newbridge”) and issued, in connection with an underwritten offering, warrants to purchase 3,564,183 shares of the Company’s common stock (the “2023 Warrants”) with the 2023 Warrants having an exercise price of $1.22 per share. As previously disclosed, in March 2025, the Company issued, in connecti…
Unregistered Sales of Equity Securities. The Company issued the New Warrants in reliance on the exemption provided by Section 3(a)(9) of the Securities Act as involving an exchange by the Company exclusively with its security holders, Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and Rule 506 promulgated thereunder and in reliance on similar exemptions under applicable state laws with such reliance on Rule 506 based in part upon a representation of eac…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 30, 2025, Modular Medical Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock (“Common Stock”) for the 30 consecutive business days ending on June 27, 2025, the Company no longer meets the requirement to maintain a minimum bid price of $1 pe…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers Non-Employee Director Appointments Effective May 22, 2025, the board of directors (the “Board”) of Modular Medical, Inc. (the “Company”) appointed Jeffrey Goldberg as a member of the Board. Mr. Goldberg, 59, is an experienced executive who currently and in the past has served as a member and chair of the board of directors of multiple companies. Sinc…
Entry into a Material Definitive Agreement. Private Placement On March 20, 2025, Modular Medical, Inc. (the “Company”) entered into Securities Purchase Agreements (the “Purchase Agreements”) with investors (the “Investors”) for the private placement (the “Private Placement”) of 6,247,656 units (each a “Unit”), with each Unit consisting of (A) two shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) and (B) one warrant (a “Warrant”) to purchase one share of Common…
The Securities being sold pursuant to the Purchase Agreement are being sold and issued without registration under the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and/or Rule 506 promulgated thereunder, and in reliance on similar exemptions under applicable state laws. For the Securities being sold pursuant to the Subscription Agreement, the Company replied upon the exemption from the registrat…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.